174 results on '"Knabl, Ludwig"'
Search Results
2. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
3. Blood transcriptomics analysis offers insights into variant-specific immune response to SARS-CoV-2
4. High prevalence group testing in epidemiology with geometrically inspired algorithms
5. Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
6. Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
7. Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron
8. Xanthoepocin, a photolabile antibiotic of Penicillium ochrochloron CBS 123823 with high activity against multiresistant gram-positive bacteria
9. BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant
10. Immune transcriptome analysis of COVID-19 patients infected with SARS-CoV-2 variants carrying the E484K escape mutation identifies a distinct gene module
11. BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
12. Machine Learning to Identify Critical Biomarker Profiles in New SARS-CoV-2 Variants
13. A high leukocyte count and administration of hydrocortisone hamper PCR-based diagnostics for bloodstream infections
14. Investigating the antibacterial activity of salen/salophene metal complexes: Induction of ferroptosis as part of the mode of action
15. Initial Evidence of Distinguishable Bacterial and Fungal Dysbiosis in the Skin of Patients with Atopic Dermatitis or Netherton Syndrome
16. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
17. Expression of Tissue Factor and Platelet/Leukocyte Markers on Extracellular Vesicles Reflect Platelet–Leukocyte Interaction in Severe COVID-19
18. Durability of cross-neutralizing antibodies 5.5 months after bivalent COVID-19 booster
19. Blood transcriptomics analysis offers insights into variant-specific immune response to SARS-CoV-2
20. High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl
21. Immune transcriptomes of highly exposed SARS-CoV-2 asymptomatic seropositive versus seronegative individuals from the Ischgl community
22. Durability of Cross-Neutralizing Antibodies 5.5 Months After Bivalent Coronavirus Disease 2019 Vaccine Booster.
23. Shiga toxin 2a binds antithrombin and heparin, but does not directly activate platelets
24. Omicron (B.1.1.529) BA.1 or BA.2-related effects on immune responses in previously naïve versus imprinted individuals: immune imprinting as an advantage in the humoral immune response against novel variants
25. Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
26. Comprehensive alternative splicing recovery needs 200 million reads
27. Influence of antibiotic treatment on the detection of S. aureus in whole blood following pathogen enrichment
28. “Enhanced acquisition of antibiotic-resistant intestinal E. coli during the first year of life assessed in a prospective cohort study”
29. Insights into SARS-CoV-2 Immune Responses, Disease Severity, and Optimal Sequencing Depth
30. Molecular biological techniques in infectiology
31. Reduced sensitivity of antibody tests after omicron infection
32. Outbreak report: a nosocomial outbreak of vancomycin resistant enterococci in a solid organ transplant unit
33. Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients
34. BA.2 omicron differs immunologically from both BA.1 omicron and pre-omicron variants
35. Immune transcriptome and antibody response in adult-onset Still’s disease with mild flare following administration of mRNA vaccine BNT162b2
36. Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection
37. Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients
38. mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
39. Prior vaccination enables a more robust immune response to Omicron infection
40. Genetic immune response and antibody repertoire of heterologous ChAdOx1-BNT162b2 vaccination in a Korean cohort
41. Neutralization profile of Omicron variant convalescent individuals
42. Additional file 1 of Xanthoepocin, a photolabile antibiotic of Penicillium ochrochloron CBS 123823 with high activity against multiresistant gram-positive bacteria
43. Impact of BNT162b First Vaccination on the Immune Transcriptome of Elderly Patients Infected with the B.1.351 SARS-CoV-2 Variant
44. Systemic Inflammation and Complement Activation Parameters Predict Clinical Outcome of Severe SARS-CoV-2 Infections
45. Robust immune response to the BNT162b mRNA vaccine in an elderly population vaccinated 15 months after recovery from COVID-19
46. Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl
47. Immune transcriptomes from hospitalized patients infected with the SARS-CoV-2 variants B.1.1.7 and B.1.1.7 carrying the E484K escape mutation
48. Systemic Inflammation and Complement Activation Parameters Predict Clinical Outcome of Severe SARS-CoV-2 Infections
49. Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl
50. Follow-up study in the ski-resort Ischgl: Antibody and T cell responses to SARS-CoV-2 persisted for up to 8 months after infection and transmission of virus was low even during the second infection wave in Austria
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.